Europe Non Invasive Prenatal Testing Market Size & Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.

13-24 weeks was the largest segment with a revenue share of 51.72% in 2022. Horizon Databook has segmented the Europe non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.

Initiatives to improve pricing policies and innovation in this field may revive the already matured Europe non-invasive prenatal testing market, which may boost the market over the forecast period. The percentage of women who undergo NIPT in Germany is more than the European average, which is more than 50%. Moreover, liberal regulations in several countries for aneuploidy screening are expected to drive market growth. Tissue matching through HLA typing is also allowed in France. However, sex selection of embryos is allowed for medical purposes only. 

In addition, Assisted Reproductive Technology (ART) is allowed to be performed only for heterosexual couples if they are married for at least two years before the procedure is performed. Moreover, since NIPT was introduced in the region in 2011, it has gained popularity quickly and companies are forming partnerships and collaborations to explore the market. For instance, in January 2022, QIAGEN entered into a collaboration with Atila BioSystems to offer a NIPT solution to the company’s dPCR franchise. QIAcuity is expanding into new research areas as a very reliable and cost-effective dPCR system. 

Around 14 nations in the region have implemented NIPT in their national programs/policies. In addition, the Netherlands and Belgium have offered NIPT to all risk groups of pregnant women. However, in other nations, it is limited to high-risk pregnant women only after their first-trimester screening. The fact that only 25% of European women are opting for NIPT reveals a huge untapped opportunity in the market.